ELSEVIER

Diabetes Research and Clinical Practice 27 (1995) 241–243

DIABETES RESEARCH
AND
CLINICAL PRACTICE

Author index

Volume 27 (1995)

Agardh, C.-D., see Eckert, B. **27**, 221
Akazawa, S., see Chikuba, N. **27**, 31
Atkinson, A.B., see Ritchie, C.M. **27**, 69
Atsumi, Y., see Okazaki, R. **27**, 39

Baker, J., see Scragg, R. **27**, 181
Bannai, C., see Yamaoka, T. **27**, 165
Beatty, O.L., see Ritchie, C.M. **27**, 69
Byks, H., see Wierusz-Wysocka, B. **27**, 193

Carlson, M., see Steindel, B.S. **27**, 199
Chaowagul, W., see Earls Davis, T.M. **27**, 171
Chikuba, N., S. Akazawa, Y. Yamaguchi, E. Kawasaki, H. Takino, M. Yoshimoto, N. Ohe, K. Yamashita, A. Yano, S. Nagataki, Immunogenetic heterogeneity in type 1 (insulin-dependent) diabetes among Japanese — class II antigen and autoimmune thyroid disease **27**, 31
Condos, P., see Martin, F.I.R. **27**, 147
Conget, I., M. Jansá, M. Vidal, J. Vidal, J.M. Manzanares, R. Gomis, Effects of an individual intensive educational control program for insulin-dependent diabetic subjects with poor metabolic control **27**, 189
Costin, G., see Steindel, B.S. **27**, 199

Dai, S., J.H. McNeill, Ascorbic acid supplementation prevents hyperlipidemia and improves myocardial performance in streptozotocin-diabetic rats **27**, 11
de Azevedo, M.J., O.L. Ramos, J. Luiz Gross, Renin-aldosterone axis in normoalbuminuric insulin-dependent diabetes mellitus patients with glomerular hyperfiltration **27**, 205
Dinççağ, N., see Tüzün, B. **27**, 153
Dryson, E., see Scragg, R. **27**, 181

Earls Davis, T.M., P. Pramukkul, Y. Suputtamongkol, W. Chaowagul, J. Levy, Glucose tolerance in rural diabetic Thais, first-degree relatives and non-diabetic controls **27**, 171
Eckert, B., E. Ryding, C.-D. Agardh, The cerebral vascular response to a rapid decrease in blood glucose to values above normal in poorly controlled Type 1 (insulin-dependent) diabetes mellitus **27**, 221

Fernlund, P., see Gottsäter, A. **27**, 133
Fujii, T., see Kamiya, A. **27**, 141
Fukasawa, H., see Hotta, N. **27**, 107

Garcia-Martinez, J.A., see Vicent, D. **27**, 27
Gomis, R., see Conget, I. **27**, 189
Gottsäter, A., M. Landin-Olsson, Å. Lernmark, P. Fernlund, G. Sundkvist, W.A. Hagopian, Glutamate decarboxylase antibody levels predict rate of β-cell decline in adult-onset diabetes **27**, 133

Hadden, D.R., see Ritchie, C.M. **27**, 69
Hagopian, W.A., see Gottsäter, A. **27**, 133
Hamada, Y., see Hotta, N. **27**, 107
Hara, T., see Hotta, N. **27**, 107
Hasegawa, K., see Sasaki, A. **27**, 77
Hirashima, T., K. Kawano, S. Mori, K. Matsumoto, T. Natori, A diabetogenic gene (*ODB-1*) assigned to the X-chromosome in OLETF rats **27**, 91
Holdaway, I., see Scragg, R. **27**, 181
Horiuchi, N., see Sasaki, A. **27**, 77
Hotta, N., H. Kakuta, H. Fukasawa, N. Koh, F. Sakakibara, J. Nakamura, Y. Hamada, T. Wakao, T. Hara, K. Mori, K. Naruse, E. Nakashima, S. Inukai, N. Sakamoto, Effect of a potent new aldose reductase inhibitor, (5-(3-thienyl)tetrazol-1-yl)acetic acid (TAT), on diabetic neuropathy in rats **27**, 107
Hulinska, H., see Hulinsky, I. **27**, 119
Hulinsky, I., H. Hulinska, M. Silink, DNA synthesis in cultured neonatal rat islets — a comparison of two methods **27**, 119
Hyogo Pravastatin Study G, see Kazumi, T. **27**, 61

Inoue, Y., K. Tanigawa, S. Nakamura, G. Xu, M. Kawaguchi, Y. Kato, K. Tamura, Lack of effect of CS-045, a new antidiabetic agent, on insulin secretion in the remnant pancreas after 90% pancreatectomy in rats **27**, 19
Inoue, Y., see Nakamura, S. **27**, 51
Inukai, S., see Hotta, N. **27**, 107
Ishida, Y., see Kazumi, T. **27**, 61
Itakura, M., see Yamaoka, T. **27**, 165

Iwatani, I., see Kazumi, T. **27**, 61

Jansá, M., see Conget, I. **27**, 189

Kaźmierczak, M., see Wierusz-Wysocka, B. **27**, 193
Kakuta, H., see Hotta, N. **27**, 107
Kamiya, A., I. Ohsawa, T. Fujii, M. Nagai, K. Yamanouchi, Y. Oshida, Y. Sato, A clinical survey on the compliance of exercise therapy for diabetic outpatients **27**, 141
Kamzoul, B.A., see Tjon-A.-Tsien, A.M.L. **27**, 211
Kasuga, M., see Kazumi, T. **27**, 61
Kato, Y., see Inoue, Y. **27**, 19
Kato, Y., see Nakamura, S. **27**, 51
Kaufman, F.R., see Steindel, B.S. **27**, 199
Kawaguchi, M., see Inoue, Y. **27**, 19
Kawaguchi, M., see Nakamura, S. **27**, 51
Kawano, K., see Hirashima, T. **27**, 91
Kawasaki, E., see Chikuba, N. **27**, 31
Kazumi, T., G. Yoshino, Y. Ishida, I. Iwatani, S. Morita, M. Tateiwa, M. Kasuga, A. Hyogo Pravastatin Study G, Long-term efficacy and tolerability of pravastatin in hypercholesterolemia in patients with non-insulin-dependent diabetes mellitus **27**, 61
Kennedy, L., see Ritchie, C.M. **27**, 69
Kim, S.W., see Lee, K.-U. **27**, 159
Ko, K.S., see Lee, K.-U. **27**, 159
Koh, N., see Hotta, N. **27**, 107
Kojima, K., Y. Totsuka, Anemia due to reduced serum erythropoietin concentration in non-uremic diabetic patients **27**, 229

Landin-Olsson, M., see Gottsäter, A. **27**, 133
Lee, K.-U., S.W. Kim, J.Y. Park, K.S. Ko, B.D. Rhee, H.K. Min, Clinical heterogeneity of insulin dependent diabetes mellitus in Korea **27**, 159
Lemkes, H.H.P., see Tjon-A.-Tsien, A.M.L. **27**, 211
Lernmark, Å., see Gottsäter, A. **27**, 133
Levy, J., see Earls Davis, T.M. **27**, 171
Luiz Gross, J., see de Azevedo, M.J. **27**, 205

Malaisse, W.J., see Vicent, D. **27**, 27
Manzanares, J.M., see Conget, I. **27**, 189
Martin, F.I.R., S. Ratnaike, A. Wootton, P. Condos, P.E.N. Suter, The 75 g oral glucose tolerance in pregnancy **27**, 147
Maruyama, K., see Okazaki, R. **27**, 39
Matsuki, H., see Okazaki, R. **27**, 39
Matsumoto, K., see Hirashima, T. **27**, 91
Matsuoka, K., see Okazaki, R. **27**, 39
McKnight, J.A., see Ritchie, C.M. **27**, 69
McNeill, J.H., see Dai, S. **27**, 11
Metcalf, P., see Scragg, R. **27**, 181
Min, H.K., see Lee, K.-U. **27**, 159
Minareci, Ö., see Tüzün, B. **27**, 153
Mizuno, A., see Okauchi, N. **27**, 97
Mohan, V., G. Premalatha, N.G. Sastry, Peripheral vascular disease in non-insulin-dependent diabetes mellitus in South India **27**, 235

Mori, K., see Hotta, N. **27**, 107
Mori, S., see Hirashima, T. **27**, 91
Morita, S., see Kazumi, T. **27**, 61

Nagai, M., see Kamiya, A. **27**, 141
Nagami, H., see Nakamura, S. **27**, 51
Nagataki, S., see Chikuba, N. **27**, 31
Nakamura, J., see Hotta, N. **27**, 107
Nakamura, S., K. Tanigawa, M. Kawaguchi, Y. Inoue, G. Xu, H. Nagami, M. Teramoto, Y. Kato, K. Tamura, Effect of chronic vanadate administration in partially depancreatized rats **27**, 51
Nakamura, S., see Inoue, Y. **27**, 19
Nakashima, E., see Hotta, N. **27**, 107
Naruse, K., see Hotta, N. **27**, 107
Natori, T., see Hirashima, T. **27**, 91

Oda, A., see Yamaoka, T. **27**, 165
Ohe, N., see Chikuba, N. **27**, 31
Ohsawa, I., see Kamiya, A. **27**, 141
Okauchi, N., A. Mizuno, S. Yoshimoto, M. Zhu, T. Sano, K. Shima, Is caloric restriction effective in preventing diabetes mellitus in the Otsuka Long Evans Tokushima Fatty Rat, a model of spontaneous non-insulin-dependent diabetes mellitus? **27**, 97
Okazaki, I., see Okazaki, R. **27**, 39
Okazaki, R., K. Matsuoka, Y. Atsumi, K. Maruyama, H. Matsuki, I. Okazaki, Serum concentrations of basement membrane proteins in NIDDM as a prognostic marker for nephropathy **27**, 39
Oshida, Y., see Kamiya, A. **27**, 141
Öztürk, S., see Tüzün, B. **27**, 153

Park, J.Y., see Lee, K.-U. **27**, 159
Patel, K.P., P.L. Zhang, Baroreflex function in streptozotocin (STZ) induced diabetic rats **27**, 1
Pramukkul, P., see Earls Davis, T.M. **27**, 171
Prasanna, B.M., see Sidhu, S.S. **27**, 127
Premalatha, G., see Mohan, V. **27**, 235

Ramos, O.L., see de Azevedo, M.J. **27**, 205
Ratnaike, S., see Martin, F.I.R. **27**, 147
Rhee, B.D., see Lee, K.-U. **27**, 159
Ritchie, C.M., O.L. Beatty, J.A. McKnight, D.R. Hadden, L. Kennedy, A.B. Atkinson, Prevalence of hypertension and albuminuria in a teaching hospital diabetes clinic **27**, 69
Roe, T.R., see Steindel, B.S. **27**, 199
Ryding, E., see Eckert, B. **27**, 221

Sakakibara, F., see Hotta, N. **27**, 107
Sakamoto, N., see Hotta, N. **27**, 107
Sano, T., see Okauchi, N. **27**, 97
Sasaki, A., N. Horiuchi, K. Hasegawa, M. Uehara, Mortality from coronary heart disease and cerebrovascular disease and associated risk factors in diabetic patients in Osaka District, Japan **27**, 77
Sastry, N.G., see Mohan, V. **27**, 235

Satman, I., see Tüzün, B. **27**, 153
Sato, Y., see Kamiya, A. **27**, 141
Scragg, R., I. Holdaway, V. Singh, P. Metcalf, J. Baker, E. Dryson, Serum 25-hydroxyvitamin D_3 levels decreased in impaired glucose tolerance and diabetes mellitus **27**, 181
Shah, P., see Sidhu, S.S. **27**, 127
Shima, K., see Okauchi, N. **27**, 97
Sidhu, S.S., P. Shah, B.M. Prasanna, S.S. Srikanta, R.K. Tandon, Chronic calcific pancreatitis of the tropics (CCPT): spectrum and correlates of exocrine and endocrine pancreatic dysfunction **27**, 127
Silink, M., see Hulinsky, I. **27**, 119
Singh, V., see Scragg, R. **27**, 181
Srikanta, S.S., see Sidhu, S.S. **27**, 127
Steindel, B.S., T.R. Roe, G. Costin, M. Carlson, F.R. Kaufman, Continuous subcutaneous insulin infusion (CSII) in children and adolescents with chronic poorly controlled type 1 diabetes mellitus **27**, 199
Sundkvist, G., see Gottsäter, A. **27**, 133
Suputtamongkol, Y., see Earls Davis, T.M. **27**, 171
Suter, P.E.N., see Martin, F.I.R. **27**, 147

Takino, H., see Chikuba, N. **27**, 31
Tamura, K., see Inoue, Y. **27**, 19
Tamura, K., see Nakamura, S. **27**, 51
Tandon, R.K., see Sidhu, S.S. **27**, 127
Tanigawa, K., see Inoue, Y. **27**, 19
Tanigawa, K., see Nakamura, S. **27**, 51
Tateiwa, M., see Kazumi, T. **27**, 61
Temel Yilmaz, M., see Tüzün, B. **27**, 153
Teramoto, M., see Nakamura, S. **27**, 51
Tjon-A.-Tsien, A.M.L., J.G. van Dijk, E.A. van der Velde, B.A. Kamzoul, H.H.P. Lemkes, Determinants of vibration perception thresholds in IDDM and NIDDM patients **27**, 211
Totsuka, Y., see Kojima, K. **27**, 229
Tüzün, B., Y. Tüzün, N. Dinççağ, Ö. Minareci, S. Öztürk, M. Temel Yilmaz, I. Satman, H. Yazici, Diabetic sclerodactyly **27**, 153
Tüzün, Y., see Tüzün, B. **27**, 153

Uehara, M., see Sasaki, A. **27**, 77

Valverde, I., see Vicent, D. **27**, 27
van der Velde, E.A., see Tjon-A.-Tsien, A.M.L. **27**, 211
van Dijk, J.G., see Tjon-A.-Tsien, A.M.L. **27**, 211
Vicent, D., J.A. Garcia-Martinez, M.L. Villanueva-Peñacarrillo, I. Valverde, W.J. Malaisse, Stimulation of insulin secretion and potentiation of glibenclamide-induced insulin release by the dimethyl ester of glutamic acid in anaesthetized rats **27**, 27
Vidal, J., see Conget, I. **27**, 189
Vidal, M., see Conget, I. **27**, 189
Villanueva-Peñacarrillo, M.L., see Vicent, D. **27**, 27

Wakao, T., see Hotta, N. **27**, 107
Wierusz-Wysocka, B., H. Wysocki, H. Byks, D. Zozulińska, A. Wykrętowicz, M. Kaźmierczak, Metabolic control quality and free radical activity in diabetic patients **27**, 193
Wootton, A., see Martin, F.I.R. **27**, 147
Wykrętowicz, A., see Wierusz-Wysocka, B. **27**, 193
Wysocki, H., see Wierusz-Wysocka, B. **27**, 193

Xu, G., see Inoue, Y. **27**, 19
Xu, G., see Nakamura, S. **27**, 51

Yamaguchi, Y., see Chikuba, N. **27**, 31
Yamanouchi, K., see Kamiya, A. **27**, 141
Yamaoka, T., A. Oda, C. Bannai, M. Itakura, K. Yamashita, The effect of non-enzymatic glycation on recombinant human aldose reductase **27**, 165
Yamashita, K., see Chikuba, N. **27**, 31
Yamashita, K., see Yamaoka, T. **27**, 165
Yano, A., see Chikuba, N. **27**, 31
Yazici, H., see Tüzün, B. **27**, 153
Yoshimoto, M., see Chikuba, N. **27**, 31
Yoshimoto, S., see Okauchi, N. **27**, 97
Yoshino, G., see Kazumi, T. **27**, 61

Zhang, P.L., see Patel, K.P. **27**, 1
Zhu, M., see Okauchi, N. **27**, 97
Zozulińska, D., see Wierusz-Wysocka, B. **27**, 193

ELSEVIER

Diabetes Research and Clinical Practice 27 (1995) 245–248

DIABETES RESEARCH AND CLINICAL PRACTICE

Subject index

Volume 27 (1995)

Abdominal fat; Non-insulin-dependent diabetes mellitus; Caloric restriction; Insulin resistance **27**, 97

Adolescents; Continuous subcutaneous insulin infusion; CSII; Non-adherence; Children **27**, 199

Albuminuria; Hypertension; Insulin treated diabetes; Non-insulin treated diabetes; Nephropathy **27**, 69

Aldose reductase; Non-enzymatic glycation; Aldose reductase inhibitor **27**, 165

Aldose eductase inhibitor; Aldose reductase; Non-enzymatic glycation **27**, 165

Aldose reductase inhibitor; Motor nerve conduction velocity; Sciatic nerve blood flow; Sorbitol; Myo-inositol **27**, 107

Anemia; Erythropoietin; Autonomic neuropathy; Diabetes mellitus **27**, 229

Arigiotensin II; Baroreflex; Renal nerves; Vasopressin **27**, 1

Ascorbic acid; Diabetes; Cardiac dysfunction; Hyperlipidemia; Rat **27**, 11

Autoantigen; Autoimmunity; β-Cell function; Glutamate decarboxylase (GAD) **27**, 133

Autoimmune thyroid disease; Type 1 (insulin-dependent) diabetes mellitus; Japanese; Class II antigen **27**, 31

Autoimmunity; Autoantigen; β-Cell function; Glutamate decarboxylase (GAD) **27**, 133

Autonomic neuropathy; Erythropoietin; Anemia; Diabetes mellitus **27**, 229

B-cell area; 90% Pancreatectomy; Vanadate; Insulin therapy **27**, 51

Baroreflex; Renal nerves; Arigiotensin II; Vasopressin **27**, 1

Basement membrane; Microangiopathy; Nephropathy; Type IV collagen; Laminin; Prognosis **27**, 39

Beta-cell function; Non-insulin-dependent diabetes mellitus (NIDDM); Insulin sensitivity; Thrifty genotype; Continuous infusion of glucose with model assessment (CIGMA) **27**, 171

BrDU; Islet cell growth; Tissue culture; Thymidine **27**, 119

C-peptide; Insulin-dependent diabetes mellitus; Classification; Heterogeneity; Onset age **27**, 159

Caloric restriction; Non-insulin-dependent diabetes mellitus; Insulin resistance; Abdominal fat **27**, 97

Captopril; Renin-aldosterone axis; Insulin-dependent diabetes mellitus; Glomerular hyperfiltration **27**, 205

Cardiac dysfunction; Ascorbic acid; Diabetes; Hyperlipidemia; Rat **27**, 11

β-Cell function; Autoimmunity; Autoantigen; Glutamate decarboxylase (GAD) **27**, 133

Cerebral blood flow; Cerebral vascular response; Lowering of blood glucose; Poorly controlled diabetes mellitus **27**, 221

Cerebral vascular response; Cerebral blood flow; Lowering of blood glucose; Poorly controlled diabetes mellitus **27**, 221

Cerebrovascular disease; NIDDM; Coronary heart disease; Risk factor; Serum cholesterol **27**, 77

Children; Continuous subcutaneous insulin infusion; CSII; Non-adherence; Adolescents **27**, 199

Chronic calcific pancreatitis; Tropics; Exocrine; Endocrine; Pancreatic dysfunction **27**, 127

Class II antigen; Type 1 (insulin-dependent) diabetes mellitus; Autoimmune thyroid disease; Japanese **27**, 31

Classification; Insulin-dependent diabetes mellitus; Heterogeneity; C-peptide; Onset age **27**, 159

Compliance; Diabetes; Exercise **27**, 141

Continuous infusion of glucose with model assessment (CIGMA); Non-insulin-dependent diabetes mellitus (NIDDM); Beta-cell function; Insulin sensitivity; Thrifty genotype **27**, 171

Continuous subcutaneous insulin infusion; CSII; Non-adherence; Children; Adolescents **27**, 199

Coronary heart disease; NIDDM; Cerebrovascular disease; Risk factor; Serum cholesterol **27**, 77

CS-045; 90% Pancreatectomy; Insulin pump; Insulin secretion; Perfused pancreas **27**, 19

CSII; Continuous subcutaneous insulin infusion; Non-adherence; Children; Adolescents **27**, 199

Diabetes; Ascorbic acid; Cardiac dysfunction; Hyperlipidemia; Rat **27**, 11

Diabetes; Exercise; Compliance **27**, 141

Diabetes educational program; Poor metabolic control **27**, 189

Diabetes mellitus; Erythropoietin; Anemia; Autonomic neuropathy **27**, 229

Diabetes mellitus; Oxidative stress; Metabolic control; Hydrogen peroxide; Malonyldialdehyde **27**, 193

Diabetes mellitus; Vitamin D; Ethnic groups **27**, 181

Diabetic cheiroarthropathy; Sclerodactyly; Limited joint mobility **27**, 153

Diabetic complication; Peripheral neuropathy; Vibration perception threshold; Diagnostic validity; Sensory threshold **27**, 211

Diagnosis; Gestational diabetes; 75 g Glucose tolerance test; Pregnancy **27**, 147

Diagnostic validity; Diabetic complication; Peripheral neuropathy; Vibration perception threshold; Sensory threshold **27**, 211

Doppler study; Peripheral vascular disease; NIDDM; South India **27**, 235

Endocrine; Chronic calcific pancreatitis; Tropics; Exocrine; Pancreatic dysfunction **27**, 127

Erythropoietin; Anemia; Autonomic neuropathy; Diabetes mellitus **27**, 229

Ethnic groups; Vitamin D; Diabetes mellitus **27**, 181

Exercise; Diabetes; Compliance **27**, 141

Exocrine; Chronic calcific pancreatitis; Tropics; Endocrine; Pancreatic dysfunction **27**, 127

Gestational diabetes; 75 g Glucose tolerance test; Pregnancy; Diagnosis **27**, 147

Glibenclamide; Glutamic acid dimethyl ester; Insulin secretion **27**, 27

Glomerular hyperfiltration; Renin-aldosterone axis; Insulin-dependent diabetes mellitus; Captopril **27**, 205

75 g Glucose tolerance test; Gestational diabetes; Pregnancy; Diagnosis **27**, 147

Glutamate decarboxylase (GAD); Autoimmunity; Autoantigen; β-Cell function **27**, 133

Glutamic acid dimethyl ester; Glibenclamide; Insulin secretion **27**, 27

Hereditary; Otsuka Long-Evans Tokushima Fatty; Non-insulin-dependent diabetes mellitus; X- chromosome **27**, 91

Heterogeneity; Insulin-dependent diabetes mellitus; Classification; C-peptide; Onset age **27**, 159

Hydrogen peroxide; Diabetes mellitus; Oxidative stress; Metabolic control; Malonyldialdehyde **27**, 193

Hyperlipidemia; Ascorbic acid; Diabetes; Cardiac dysfunction; Rat **27**, 11

Hypertension; Insulin treated diabetes; Non-insulin treated diabetes; Albuminuria; Nephropathy **27**, 69

Hypertension; Pravastatin; LDL cholesterol; NIDDM; Obesity; Proteinuria **27**, 61

Insulin pump; 90% Pancreatectomy; CS-045; Insulin secretion; Perfused pancreas **27**, 19

Insulin resistance; Non-insulin-dependent diabetes mellitus; Caloric restriction; Abdominal fat **27**, 97

Insulin secretion; 90% Pancreatectomy; CS-045; Insulin pump; Perfused pancreas **27**, 19

Insulin secretion; Glutamic acid dimethyl ester; Glibenclamide **27**, 27

Insulin sensitivity; Non-insulin-dependent diabetes mellitus (NIDDM); Beta-cell function; Thrifty genotype; Continuous infusion of glucose with model assessment (CIGMA) **27**, 171

Insulin therapy; 90% Pancreatectomy; Vanadate; B-cell area **27**, 51

Insulin treated diabetes; Hypertension; Non-insulin treated diabetes; Albuminuria; Nephropathy **27**, 69

Insulin-dependent diabetes mellitus; Classification; Heterogeneity; C-peptide; Onset age **27**, 159

Insulin-dependent diabetes mellitus; Renin-aldosterone axis; Glomerular hyperfiltration; Captopril **27**, 205

Islet cell growth; Tissue culture; BrDU; Thymidine **27**, 119

Japanese; Type 1 (insulin-dependent) diabetes mellitus; Autoimmune thyroid disease; Class II antigen **27**, 31

Laminin; Microangiopathy; Nephropathy; Basement membrane; Type IV collagen; Prognosis **27**, 39

LDL cholesterol; Pravastatin; NIDDM; Hypertension; Obesity; Proteinuria **27**, 61

Limited joint mobility; Sclerodactyly; Diabetic cheiroarthropathy **27**, 153

Lowering of blood glucose; Cerebral blood flow; Cerebral vascular response; Poorly controlled diabetes mellitus **27**, 221

Malonyldialdehyde; Diabetes mellitus; Oxidative stress; Metabolic control; Hydrogen peroxide **27**, 193

Metabolic control; Diabetes mellitus; Oxidative stress; Hydrogen peroxide; Malonyldialdehyde **27**, 193

Microangiopathy; Nephropathy; Basement membrane; Type IV collagen; Laminin; Prognosis **27**, 39

Motor nerve conduction velocity; Aldose reductase inhibitor; Sciatic nerve blood flow; Sorbitol; Myo-inositol **27**, 107

Myo-inositol; Aldose reductase inhibitor; Motor nerve conduction velocity; Sciatic nerve blood flow; Sorbitol **27**, 107

Nephropathy; Hypertension; Insulin treated diabetes; Non-insulin treated diabetes; Albuminuria **27**, 69

Nephropathy; Microangiopathy; Basement membrane; Type IV collagen; Laminin; Prognosis **27**, 39

NIDDM; Coronary heart disease; Cerebrovascular disease; Risk factor; Serum cholesterol **27**, 77

NIDDM; Peripheral vascular disease; South India; Doppler study **27**, 235

NIDDM; Pravastatin; LDL cholesterol; Hypertension; Obesity; Proteinuria **27**, 61

Non-adherence; Continuous subcutaneous insulin infusion; CSII; Children; Adolescents **27**, 199

Non-enzymatic glycation; Aldose reductase; Aldose reductase inhibitor **27**, 165

Non-insulin treated diabetes; Hypertension; Insulin treated diabetes; Albuminuria; Nephropathy **27**, 69

Non-insulin-dependent diabetes mellitus (NIDDM); Beta-cell function; Insulin sensitivity; Thrifty genotype; Continuous infusion of glucose with model assessment (CIGMA) **27**, 171

Non-insulin-dependent diabetes mellitus; Caloric restriction; Insulin resistance; Abdominal fat **27**, 97

Non-insulin-dependent diabetes mellitus; Otsuka Long-Evans Tokushima Fatty; Hereditary; X- chromosome **27**, 91

Obesity; Pravastatin; LDL cholesterol; NIDDM; Hypertension; Proteinuria **27**, 61

Onset age; Insulin-dependent diabetes mellitus; Classification; Heterogeneity; C-peptide **27**, 159

Otsuka Long-Evans Tokushima Fatty; Non-insulin-dependent diabetes mellitus; Hereditary; X- chromosome **27**, 91

Oxidative stress; Diabetes mellitus; Metabolic control; Hydrogen peroxide; Malonyldialdehyde **27**, 193

90% Pancreatectomy; CS-045; Insulin pump; Insulin secretion; Perfused pancreas **27**, 19

90% Pancreatectomy; Vanadate; Insulin therapy; B-cell area **27**, 51

Pancreatic dysfunction; Chronic calcific pancreatitis; Tropics; Exocrine; Endocrine **27**, 127

Perfused pancreas; 90% Pancreatectomy; CS-045; Insulin pump; Insulin secretion **27**, 19

Peripheral neuropathy; Diabetic complication; Vibration perception threshold; Diagnostic validity; Sensory threshold **27**, 211

Peripheral vascular disease; NIDDM; South India; Doppler study **27**, 235

Poor metabolic control; Diabetes educational program **27**, 189

Poorly controlled diabetes mellitus; Cerebral blood flow; Cerebral vascular response; Lowering of blood glucose **27**, 221

Pravastatin; LDL cholesterol; NIDDM; Hypertension; Obesity; Proteinuria **27**, 61

Pregnancy; Gestational diabetes; 75 g Glucose tolerance test; Diagnosis **27**, 147

Prognosis; Microangiopathy; Nephropathy; Basement membrane; Type IV collagen; Laminin **27**, 39

Proteinuria; Pravastatin; LDL cholesterol; NIDDM; Hypertension; Obesity **27**, 61

Rat; Ascorbic acid; Diabetes; Cardiac dysfunction; Hyperlipidemia **27**, 11

Renal nerves; Baroreflex; Arigiotensin II; Vasopressin **27**, 1

Renin-aldosterone axis; Insulin-dependent diabetes mellitus; Glomerular hyperfiltration; Captopril **27**, 205

Risk factor; NIDDM; Coronary heart disease; Cerebrovascular disease; Serum cholesterol **27**, 77

Sciatic nerve blood flow; Aldose reductase inhibitor; Motor nerve conduction velocity; Sorbitol; Myo-inositol **27**, 107

Sclerodactyly; Diabetic cheiroarthropathy; Limited joint mobility **27**, 153

Sensory threshold; Diabetic complication; Peripheral neuropathy; Vibration perception threshold; Diagnostic validity **27**, 211

Serum cholesterol; NIDDM; Coronary heart disease; Cerebrovascular disease; Risk factor **27**, 77

Sorbitol; Aldose reductase inhibitor; Motor nerve conduction velocity; Sciatic nerve blood flow; Myo-inositol **27**, 107

South India; Peripheral vascular disease; NIDDM; Doppler study **27**, 235

Thrifty genotype; Non-insulin-dependent diabetes mellitus (NIDDM); Beta-cell function; Insulin sensitivity; Continuous infusion of glucose with model assessment (CIGMA) **27**, 171

Thymidine; Islet cell growth; Tissue culture; BrDU **27**, 119

Tissue culture; Islet cell growth; BrDU; Thymidine **27**, 119

Tropics; Chronic calcific pancreatitis; Exocrine; Endocrine; Pancreatic dysfunction **27**, 127

Type 1 (insulin-dependent) diabetes mellitus; Autoimmune thyroid disease; Japanese; Class II antigen **27**, 31

Type IV collagen; Microangiopathy; Nephropathy; Basement membrane; Laminin; Prognosis **27**, 39

Vanadate; 90% Pancreatectomy; Insulin therapy; B-cell area **27**, 51

Vasopressin; Baroreflex; Renal nerves; Arigiotensin II **27**, 1

Vibration perception threshold; Diabetic complication; Peripheral neuropathy; Diagnostic validity; Sensory threshold **27**, 211

Vitamin D; Diabetes mellitus; Ethnic groups **27**, 181

X-chromosome; Otsuka Long-Evans Tokushima Fatty; Non-insulin-dependent diabetes mellitus; Hereditary **27**, 91